Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Threitolceramide 6 - Portage Biotech

Next Previous
Drug Profile

Threitolceramide 6 - Portage Biotech

Alternative Names: IMM-60; PORT-2; ThrCer6

Latest Information Update: 10 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ludwig Institute for Cancer Research; University of Oxford
  • Developer Portage Biotech
  • Class Alcohols; Alkanes; Antineoplastics; Ceramides; Ethers; Small molecules
  • Mechanism of Action Immunostimulants; Natural killer T cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Malignant melanoma; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 22 Apr 2024 Portage Biotech terminates Phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease) in United Kingdom (IV, infusion) (NCT0570982)
  • 22 Apr 2024 Portage Biotech terminates Phase-I/II clinical trials in Malignant melanoma (Combination therapy, Late-stage disease) in United Kingdom (IV, infusion) due to prioritization of other pipeline assets (NCT0570982)
  • 04 Jan 2024 Suspended - Phase-I/II for Malignant melanoma (Combination therapy, Late-stage disease) in United Kingdom (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top